CO2022006708A2 - Anticuerpos trem2 y usos de estos - Google Patents

Anticuerpos trem2 y usos de estos

Info

Publication number
CO2022006708A2
CO2022006708A2 CONC2022/0006708A CO2022006708A CO2022006708A2 CO 2022006708 A2 CO2022006708 A2 CO 2022006708A2 CO 2022006708 A CO2022006708 A CO 2022006708A CO 2022006708 A2 CO2022006708 A2 CO 2022006708A2
Authority
CO
Colombia
Prior art keywords
trem2 antibodies
trem2
antibodies
diseases
relates
Prior art date
Application number
CONC2022/0006708A
Other languages
English (en)
Inventor
Ying Tang
Forest Hoyt Andrews
Ross Edward Fellows
Yaming Wang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2022006708A2 publication Critical patent/CO2022006708A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos TREM2 y usos de estos para tratar enfermedades tales como enfermedades neurodegenerativas.
CONC2022/0006708A 2019-11-22 2022-05-20 Anticuerpos trem2 y usos de estos CO2022006708A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962939097P 2019-11-22 2019-11-22
PCT/US2020/060663 WO2021101823A1 (en) 2019-11-22 2020-11-16 Trem2 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CO2022006708A2 true CO2022006708A2 (es) 2022-05-31

Family

ID=73790267

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0006708A CO2022006708A2 (es) 2019-11-22 2022-05-20 Anticuerpos trem2 y usos de estos

Country Status (17)

Country Link
US (1) US20220281975A1 (es)
EP (1) EP4061842A1 (es)
JP (1) JP7368624B2 (es)
KR (1) KR20220084152A (es)
CN (1) CN114667295B (es)
AU (1) AU2020387380A1 (es)
BR (1) BR112022007944A2 (es)
CA (1) CA3159055A1 (es)
CO (1) CO2022006708A2 (es)
CR (1) CR20220228A (es)
DO (1) DOP2022000104A (es)
EC (1) ECSP22041169A (es)
IL (1) IL293018A (es)
JO (1) JOP20220119A1 (es)
MX (1) MX2022006145A (es)
PE (1) PE20221337A1 (es)
WO (1) WO2021101823A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279606B (en) * 2014-08-08 2022-08-01 Alector Llc Anti-trem2 antibodies and methods of using them
CA2997960A1 (en) * 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof
WO2018015573A2 (en) * 2016-07-22 2018-01-25 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Trem2 cleavage modulators and uses thereof
PE20200148A1 (es) * 2017-08-03 2020-01-17 Alector Llc Anticuerpos anti-trem2 y metodos para utilizarlos
JP7403441B2 (ja) * 2017-09-14 2023-12-22 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
KR20200097765A (ko) * 2017-12-12 2020-08-19 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 항-trem2 항체 및 관련 방법

Also Published As

Publication number Publication date
PE20221337A1 (es) 2022-09-13
BR112022007944A2 (pt) 2022-07-12
CN114667295A (zh) 2022-06-24
JOP20220119A1 (ar) 2023-01-30
US20220281975A1 (en) 2022-09-08
JP2023502460A (ja) 2023-01-24
ECSP22041169A (es) 2022-06-30
DOP2022000104A (es) 2022-07-31
CA3159055A1 (en) 2021-05-27
MX2022006145A (es) 2022-06-17
CN114667295B (zh) 2024-03-29
EP4061842A1 (en) 2022-09-28
KR20220084152A (ko) 2022-06-21
AU2020387380A1 (en) 2022-05-26
WO2021101823A1 (en) 2021-05-27
CR20220228A (es) 2022-06-08
JP7368624B2 (ja) 2023-10-24
IL293018A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
ECSP20075198A (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos
CO2022006708A2 (es) Anticuerpos trem2 y usos de estos
CL2016002509A1 (es) Composiciones para modular la expresión de sod-1
GT201700188A (es) Anticuerpos contra tau y sus usos
ECSP19020740A (es) Anticuerpos anti-cd27
NI201700019A (es) Anticuerpos anti tigit
EA201890093A1 (ru) Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
DOP2018000040A (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
CL2016002281A1 (es) Anticuerpos de il-21
CL2018000611A1 (es) Sales de un inhibidor de pim quinasa
CR20170247A (es) 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
UY37980A (es) Compuestos novedosos para tratar enfermedades parasitarias
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
BR112022009493A2 (pt) Fabricação de do3a protegido
BR112018005999A2 (pt) métodos para a produção de intermediários de onapristona
BR112019025420A2 (pt) Compostos policíclicos e usos destes
BR112022004475A2 (pt) Proteínas de fusão nkg2d e usos das mesmas
EA201790428A1 (ru) Синтез энт-прогестерона и его промежуточных соединений